✦ LIBER ✦

A LARGE OPEN-LABEL, NON-COMPARATIVE, PHASE III STUDY OF THE MULTI-TARGETED KINASE INHIBITOR SORAFENIB IN EUROPEAN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

✍ Scribed by J. Beck; E. Verzoni; S. Negrier; U. Keilholz; C. Szczylik; S. Bracarda; C. Bokemeyer; D. Richel; M. Staehler; S. Mersmann; K. Burock; F. Erlandsson; B. Bernard

Book ID: 119619022
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 73 KB
Volume: 7
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(08)60692-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

4506 ORAL A large open-label, non-compar

4506 ORAL A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma

✍ Beck, J.; Bajetta, E.; Escudier, B.; Negrier, S.; Keilholz, U.; Szczylik, C.; Me 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

254 A SUBANALYSIS OF PATIENTS WITH AND W

254 A SUBANALYSIS OF PATIENTS WITH AND WITHOUT PRIOR NEPHRECTOMY IN A LARGE OPEN-LABEL, NON-COMPARATIVE PHASE 3 EUROPEAN ADVANCED RENAL CELL CARCINOMA (RCC) SORAFENIB STUDY (EU-ARCCS)

✍ M. Staehler; G. Procopio; U. Keilholz; S. Negrier; C. Szczylik; J. Beck; U.P. St 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 506 KB

794 ORAL Randomized Phase III trial of t

794 ORAL Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

O4 Tivozanib hydrochloride versus sorafe

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

✍ Motzer, R.; Nosov, D.; Eisen, T.; Lipatov, O.; Tomczak, P.; Lyulko, O.; Harza, M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

7132 Safety and efficacy of sorafenib in

7132 Safety and efficacy of sorafenib in patients with advanced renal cell carcinoma (RCC) with varying histologies: results from the phase 3, open access study of sorafenib in European patients with advanced RCC (EU-ARCCS)

✍ Bokemeyer, C.; Gore, M.; Bracarda, I.; Richel, N.; Staehler, D.; von der Maase, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

7130 Efficacy and safety of sorafenib in

7130 Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma (RCC) with bone metastases: results from the phase III target study

✍ Bukowski, R.; Eisen, T.E.; Stadler, W.S.; Szczylik, C.S.; Oudard, O.S.; Siebels, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB